Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review

Andrea Picchianti Diamanti, Milica Markovic, Giuseppe Argento, Simonetta Giovagnoli, Alberto Ricci, Bruno Laganà and Raffaele D’Amelio

Abstract: Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung disease (ILD) is a common pulmonary manifestation that may be related to the inflammatory process itself, infectious complications and to the treatments used. Management of patients with ILD/RA is still a challenge for clinicians, both synthetic [mainly methotrexate (MTX), leflunomide] and biologic immunosuppressors [mainly anti-tumor necrosis factor (TNF)α] have in fact been related to the onset or worsening of lung diseases with conflicting data. Here we report the case of a 61-year-old male patient with severely active early RA, previously treated with MTX, who developed subacute ILD, along with a review of ILD/RA topic. Tocilizumab (humanized monoclonal antibody against the interleukin-6 receptor) was introduced on the basis of its effectiveness in RA without concomitant MTX and the ability to overcome the profibrotic effects of interleukin (IL)-6. After 3 months of treatment the clinical condition of the patient strongly improved until it reached low disease activity. He no longer complained of cough and dyspnea and bilateral basal crackles were no more present. Considering its distinctive features, tocilizumab, in such a challenging clinical condition, appears to be a safe and effective therapy, thus it enables RA remission without deteriorating ILD, at 1-year follow up, as confirmed by ultrasonography of the affected joints and chest high-resolution computed tomography (HRCT).

Keywords: anti-TNFα agents, interstitial lung disease, rheumatoid arthritis, tocilizumab

Introduction
Rheumatoid arthritis (RA) is an inflammatory chronic autoimmune disease generally characterized by a progressive and disabling symmetric polyarthritis accompanied by specific autoantibodies. RA can also present different extrarticular manifestations involving heart, lungs and kidneys [Hallowell and Horton, 2014]. Even though the majority of RA-related deaths are linked to cardiovascular disease, pulmonary complications are common and cause 10–20% of overall mortality [Maradit-Kremers et al. 2005].

In particular interstitial lung disease (ILD) is a common pulmonary manifestation that may be related to the inflammatory process itself, infectious complications and to the treatments used. Both synthetic and biologic immunosuppressors have been related to the onset or worsening of ILD, making the adoption of safe and effective therapeutic approach difficult. Here we report the case of a 61-year-old male patient with early RA who developed subacute ILD under methotrexate (MTX) therapy, in which tocilizumab (humanized monoclonal antibody against
the interleukin-6 receptor) enables RA remission without deteriorating ILD.

Case report
In April 2013, a 61-year-old man suffering from early RA [2–10 small joints, increased erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP), positivity of anticyclic citrullinated peptide antibodies (ACPA)/rheumatoid factor (RF), symptoms lasting 1 year] came to our attention for the worsening of morning stiffness, pain and symmetrical swelling of proximal interphalangeal (PIP), metacarpophalangeal (MCP) joints and wrists.

The patient presented several comorbidities: high blood pressure, type 2 diabetes mellitus, dyslipidemia, class I obesity [body mass index (BMI) = 33.2], prostatic enlargement and depressive mood. In addition, he was a smoker [60 pack-years (PY)].

He was receiving treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids (CCS) in the medium/high doses (up to 15 mg/day prednisone). During the first visit at our division, the patient exhibited laboratory investigation that showed ESR 37 mm/h, CRP 10 mg/l, RF 122 IU/ml, ACPAs 233 IU/ml; quantiferon-TB gold test, antinuclear antibody (ANA) and extractable nuclear antigen (ENA) screening as well as complete hepatitis B and C markers were negative; blood count [white blood cells (WBC) $6.5 \times 10^3/\mu l$, granulocytes 55%, lymphocytes 35%], transaminases, creatinine and serum protein electrophoresis were normal. He did not present other clinical signs and symptoms suggestive of connective tissue disorders such as: Raynaud’s phenomenon, skin thickening, dysphagia and acid reflux, rashes, sicca syndrome, myalgia and proximal muscle weakness, nor constitutional symptoms of fever and sweats. X-ray of November 2012 documented a mild increase of the plot in the absence of clinical signs; hands and wrists X-ray reported diffuse arthropathic manifestations with initial erosions of ulnar styloid. Ultrasound of hands and wrists bilaterally demonstrated moderate proliferative, erosive and active synovitis [power Doppler (PD) III] of radiocarpal joints, moderate active (PD II) proliferative tenosynovitis of the flexor tendons of the fingers, mild proliferative synovitis of the II MCP joint (Figure 1(a,b)). On examination, he presented four tender and four swollen joints (radiocarpal and II MCP joints bilaterally). Clinimetric data showed moderate activity with disease activity score in 28 Joints (DAS28) of 4.8 and moderate disability with Health Assessment Questionnaire (HAQ) of 1.5. We also performed the Short Form Questionnaire for general well being (SF-36) to gain a deep insight of his mental and physical quality of life. He presented a severe reduction (>2 standard deviations from the

![Figure 1. Ultrasonography of the right radiocarpal joint, longitudinal scanning. (a, b) Baseline: moderate synovial hypertrophy with severe activity (power Doppler III). (c) Three months follow up: mild synovial hypertrophy with mild activity (power Doppler I).](http://tar.sagepub.com)
mean) in all the SF-36 subscales with a Physical Component Summary (PCS) of 22 and a Mental Component Summary (MCS) of 26.

MTX 15 mg/week was, therefore, introduced and progressive CCS decrease (up to 5 mg/day) started. After 2 months of therapy with MTX, the patient showed significant improvement of RA signs and symptoms. However, he began to complain of persistent dry cough and dyspnea without fever. The objective examination of the chest documented bilateral basal crackles. In suspicion of ILD, the patient was submitted to lung function tests that documented mild restrictive defect with mild reduction of CO single-breath diffusing capacity (DLCO SB 60%) and CO divided by the alveolar volume (DLCO/VA 87%; forced vital capacity 67%). High-resolution computed tomography (HRCT) showed one micronodule (5 mm) with smooth margins in subpleural parenchymal right upper lobe and notes of bilateral interstitial fibrotic striae type ‘ground glass’ more evident on the left (Figure 2(a)). MTX was interrupted and therapy with Sulphasalazine 2 g/day was introduced. The consultant pneumologist proposed to also perform a bronchoalveolar lavage (BAL).

Figure 2. Chest high resolution computed tomography representative lung layers. (a) Baseline: inflammatory interstitial thickening with ground glass pattern [red arrows]. (b) One-year follow up: reduction in size and density of the ground glass pattern.
which excluded concomitant infections and showed an increased cellularity with raised granulocytes (10%) and lymphocytes (20%), eosinophils and macrophages were within the normal range; the CD4/CD8 ratio was 1.3. The CCS dose was not increased; however, after 3 months the patient presented marked arthritic worsening with six tender and six swollen joints and a DAS28 of 5.8 (severe activity), accompanied by a deterioration of its depressive mood. Consequently, treatment with tocilizumab at recommended standard dose (8 mg/kg, total 760 mg ev/monthly) was introduced. After 3 months of treatment with tocilizumab, the clinical condition of the patient visibly improved. The clinimetric data showed low disease activity (DAS28 = 3) and a reduced disability (HAQ = 1) confirmed by the marked amelioration in all the SF-36 subscales (PCS from 22 to 33 and MCS from 26 to 43). The patient presented only one tender and swollen joint (left radiocarpic joint). Ultrasonography of hands and wrists documented a mild synovitis (PD grade I) of radiocarpic joints bilaterally (Figure 1(c)). He no longer complained of cough and dyspnea and bilateral basal crackles were no more present. After 6 months of therapy with tocilizumab, the clinical conditions of the patient were still stable (DAS28 = 3); the tests of lung function showed persistence of mild restrictive defect with normal CO diffusion (DLCO/VA 102%).

At 1-year follow up the patient showed a clinical remission (DAS28 = 2), further improvement in disability (HAQ = 0.5) and SF-36 (PCS 35; MCS 45). The objective examination of the chest was normal and the tests of lung function were stable. HRCT was repeated and it documented the reduction in size and density of ground glass area (Figure 2).

Informed consent was obtained from the patient for his information and images to be included in this article, as well as for diagnostic and therapeutic interventions. Our institution does not require ethics approval for reporting individual cases.

Discussion

In the patient here described tocilizumab was introduced on the basis of its distinctive features, such as the effectiveness in RA without concomitant MTX and the ability to overcome the profibrotic effects of IL-6. Moreover, the biological drug could safely be administered, since the BAL had enabled to exclude pulmonary infections before the start of therapy. To the best of the authors’ knowledge, this is the second case in the literature reporting tocilizumab as a possible treatment in this clinical condition.

ILD is a common pulmonary manifestation of RA that may be related to the chronic inflammation of the underlying disease, to infectious complications and to the treatments used [Hamblin and Horton, 2011]. The prevalence of clinical ILD in patients with RA has been reported by several authors in the wide range of 10–60% [Bongartz et al. 2010]. This variability may be related to lack of standardized screening protocols, including functional respiratory tests before starting immunosuppressive therapy. This may even condition the possibility of establishing a certain cause–effect relationship between drug assumption and ILD appearance/worsening. A further bias is the different sensitivity of the used diagnostic technique. In fact, it has been described in up to 80% of biopsies, 50% of chest CT and only 5% of chest X-ray [Crestani, 2005]. Mean age at the onset of lung disease is the fifth or sixth decade, with an increased prevalence in males and long-standing RA [Bilgici et al. 2005; Gochuico et al. 2008]. Smokers and patients with rheumatoid nodules, high titer of RF, ANA, ACPA, carriage of HLA-DRB1*1502 are described to be at higher risk of developing ILD, whereas disease severity seems to be an irrelevant factor [Lamblin et al. 2001; Mori et al. 2012]. Of note, the patient here described presented several of the among reported risk factors such as the RF, ACPA positivity and smoking.

Several histopathological patterns of ILD have been described: usual interstitial pneumonia (UIP) is the most frequent, followed by nonspecific interstitial pneumonia (NSIP); other patterns are less commonly observed [Koduri et al. 2010]. The incidence of ILD in RA patients is not only related to the disease itself, in fact many drugs may be associated with the development or worsening of pulmonary damage [Picchianti Diamanti et al. 2011]. The link between MTX and lung disease in RA patients has been recognized since many years and several reports have described induction or worsening of pneumonitis in a range of 0.86–6.9% of patients, with morbidity and mortality rates reaching 20% [Saravanan and Kelly, 2006]. Lung involvement may develop at any time during treatment, nevertheless it has
been described to manifest in 48% of affected patients within 32 weeks since the MTX introduction [D’Elia, 2014]. To distinguish between MTX-induced pneumonitis and RA-related ILD is crucial considering that the former can resolve with stopping MTX and continuing steroids whereas the latter needs specific treatment. Unfortunately to obtain a differential diagnosis remains a clinical challenge. In fact, MTX-related pneumonitis usually present more acutely than RA-associated ILD but the other clinical, imaging and histopathological features (i.e. dyspnea, nonproductive cough, ground glass opacities, lymphocytic alveolitis) are shared, thus rendering them sometimes indistinguishable [Saravanan and Kelly, 2004; Wells and Hirani, 2008]. An effective role in the differential diagnosis cannot be attributed either to the BAL cytological analysis. In fact it can show moderate lymphocytosis and high CD4/CD8 ratio [Fuhrman et al. 2001; Schnabel et al. 1997] in the MTX pneumonitis but these findings are nonspecific [D’Elia, 2014; Jakubovic et al. 2013].

According to the commonly accepted criteria for the diagnosis of MTX-induced pneumonitis, the case here presented can be interpreted as a probable, but not definite, case of MTX-related pneumonitis, only fulfilling five available (subacute onset dyspnea, dry cough, WBC less than $15 \times 10^9$, negative blood and BAL cultures, restrictive defect and diffusion capacity on pulmonary function test) criteria [Searles and McKendry 1987].

Furthermore, considering all of the clinical, laboratory and imaging features, an underlying RA-related ILD cannot be excluded.

Current guidelines of the British Society for Rheumatology for the management of patients with RA have proposed to perform pulmonary function tests as a screening procedure before starting MTX thus helping to identify occult lung disease [Chakravarty et al. 2008]. Despite the association between pneumonitis and MTX is generally accepted, the ILD/MTX link is not clearly demonstrated and has been questioned by other authors. Dawson and colleagues [Dawson et al. 2002] performed chest HRCT and pulmonary function test in 128 RA patients and found no differences in the dose or duration of MTX therapy in the 28 patients presenting pulmonary fibrosis, suggesting no evidence of MTX-related chronic ILD.

Finally, a recent meta-analysis of Conway and colleagues [Conway et al. 2014] have demonstrated a mild increased risk of respiratory adverse events in patients with RA treated with MTX compared with other disease-modifying antirheumatic drugs (DMARDs) and biologic agents, however not higher increased risk of death. Leflunomide is also associated to ILD in RA patients, with higher risk in pre-existing lung disease and a potential relevant impact on survival [Raj and Nugent, 2013; Sawada et al. 2009]; few data are available regarding other synthetic DMARDs [Roubille and Haraoui, 2014].

Biological agents are nowadays considered the most effective therapeutic option in RA, especially when used in patients with early onset disease or poor prognostic factors, such as high titers of autoantibodies and high disease activity as in the patient here described [Smolen et al. 2010]. However, these drugs are not free from side effects. A possible correlation with RA-ILD has in fact been reported for several biologicals. In particular, new-onset or exacerbation of ILD after administration of all anti-tumor necrosis factor alpha (anti-TNFα) agents approved for the treatment of RA (infliximab, etanercept, adalimumab, certolizumab and golimumab) have been described by a number of reports and registry data, suggesting a class effect, rather than drug adverse event [Dixon et al. 2010; Hadjinicolaou et al. 2011; Kremer et al. 1997; Koike et al. 2011; Panopoulos and Sfikakis, 2011; Pearce et al. 2012; Perez-Alvarez et al. 2011; Schuller et al. 2010; Takeuchi et al. 2008].

Perez-Alvarez and colleagues [Perez-Alvarez et al. 2011] identified 122 cases (108 RA) of new onset or exacerbation of ILD secondary to administration of biologic therapies (58 etanercept, 56 infliximab, 3 adalimumab and 5 rituximab). The poor prognosis was associated with age >65 years, late onset of symptoms, frequent use of other immunosuppressants (especially MTX), and a previous diagnosis of ILD [Perez-Alvarez et al. 2011].

A review by Panopoulos and Sfikakis [Panopoulos and Sfikakis, 2011] reported 144 cases of new onset (60%) or exacerbation of preexisting ILD (40%) in RA patients following anti-TNFα treatment (55 infliximab, 95 etanercept, and 4 adalimumab). Nakashita and colleagues retrospectively analyzed 163 patients with RA treated with biological agents (63 etanercept, 33 infliximab, 6 adalimumab, 36 tocilizumab, 25 abatacept) and
observed a prevalence of 3% of new ILD events and 24% of ILD worsening with the use of TNFα agents [higher than previously reported (0.5–0.6%) from post-marketing data surveillance] [Koike et al. 2011; Takeuchi et al. 2008], whereas tocilizumab and abatacept did not increase the prevalence of ILD events [Nakashita et al. 2014].

Despite the previously mentioned evidence, the association of anti-TNFα treatment and ILD has been recently questioned. As a matter of fact, a retrospective study including 8417 patients affected by RA, ankylosing spondylitis, psoriatic arthritis, psoriasis and inflammatory bowel disease did not present an increased rate of ILD compared with those treated with nonbiologic drugs [adjusted hazard ratio, 1.03; 95% confidence interval (CI) 0.51–2.07]; with not significant differences among anti-TNFα molecules [Herrinton et al. 2013]. In addition, in sporadic cases good results have been reported by the use of these agents in patients with RA-ILD [Bargagli et al. 2004; Vassallo et al. 2002]. These conflicting results may be explained by the complex and pleomorphic activity of TNFα and reflect the need to elucidate the relationship between anti-TNFα agents and ILD. Different studies on animal models have in fact demonstrated a profibrotic role for this molecule. Transgenic mice overexpressing murine TNFα in the lung develop a chronic lymphocytic alveolitis, the severity of which correlates with the expression of TNFα mRNA. Moreover, TNFα may upregulate TGFβ1 expression in the lungs via the activation of regulated kinase pathway in fibroblasts [Miyazaki et al. 1995; Sullivan et al. 2009]. Otherwise, mice knockout for TNFα develop a bleomycin-induced lung fibrosis that may be reverted by the administration of TNFα [Kuroki et al. 2003]; TNFα is also able to block the synthesis of collagen production and inhibits α2 collagen gene transcription in human dermal fibroblasts [Kouba et al. 1999].

Few reports of ILD onset/worsening are also present in the literature in patients receiving rituximab and abatacept therapy [Soubrier et al. 2008; Wada et al. 2012; Wagner et al. 2007].

Improvement of RA-ILD with tocilizumab has been observed in a single case report [Mohr and Jacobi, 2011]. The case of 58-year-old female patient with seropositive RA treated with MTX until she developed MTX-related ILD has been reported. The tests of lung function documented mild reduction of CO and HRCT evidenced alveolitis. Thereafter, treatment with tocilizumab was started as monotherapy. Within 16 weeks, the patient presented an improvement in the diffusion of CO, absence of dyspnea and improvement in RA disease activity. A 6-month follow-up HRCT documented disappearance of ground glass infiltrates and lack of fibrotic reorganization of the lung tissue [Mohr and Jacobi, 2011]. In contrast, other authors addressed ILD occurrence or exacerbation following tocilizumab therapy [Kawashiri et al. 2012; Wendling et al. 2013].

Conclusion
Therapeutic management of patients with ILD associated with RA is still a challenge for clinicians. In fact, most drugs used for RA treatment have been reported to be related with onset or worsening of ILD. Several reports suggest also a causative role for TNFα inhibitors in RA-ILD development/worsening; however, no definitive conclusion can be drawn hence data are conflicting and affected by several variables. Current knowledge on the role of biologics with different mechanism of action is limited. In this context, tocilizumab appears as a therapeutic strategy based on a solid rationale, considering that it can overcome the profibrotic effects of IL-6 and it is the only biologic equally effective in RA, even in the absence of concomitant MTX. Here the case of a 61-year-old male patient with early RA, previously treated with MTX who developed subacute ILD is reported. Our investigations did not confidently distinguish between MTX pneumonitis and RA related ILD; however, in such a challenging clinical condition, tocilizumab appears to be a safe and effective therapy, thus it enables RA remission without deteriorating ILD, at 1-year follow up, as confirmed by ultrasonography of the affected joints and chest HRCT.

Acknowledgements
Andrea Picchianti Diamanti and Milica Markovic contributed equally to this work.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References
Bargagli, E., Galeazzi, M. and Rottoli, P. (2004) Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J 24: 708.

Bilgici, A., Ulusoy, H., Kuru, O., Çelenk, C., Ünsal, M. and Danaci, M. (2005) Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 25: 429–435.

Bongartz, T., Nannini, C., Medina-Velasquez, Y., Achenbach, S., Crowson, C., Ryu, J. et al. (2010) Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 62: 1583–1591.

Chakravarty, K., McDonald, H., Pullar, T., Taggart, A., Chalmers, R., Oliver, S. et al. (2008) BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of dermatologists. Rheumatology 47: 924–925.

Conway, R., Low, C., Coughlan, R., O'Donnell, M. and Carey, J. (2014) Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol 66: 803–812.

Crestani, B. (2005) The respiratory system in connective tissue disorders. Allergy 60: 715–734.

D’Elia, T. (2014) Methotrexate-induced pneumonitis: heterogeneity of bronchoalveolar lavage and differences between cancer and rheumatoid arthritis. Inflamm Allergy Drug Targets 13(1): 25–33.

Dawson, J., Graham, D., Desmond, J., Fewins, H. and Lynch, M. (2002) Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology 41: 262–267.

Dixon, W., Hyrich, K., Watson, K. and Lunt, M.; BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. (2010) Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 69: 1086–1091.

Fuhrman, C., Parrot, A., Wislez, M., Prigent, H., Boussaud, V., Bernaudin, J. et al. (2001) Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 164: 1186–1191.

Gochuico, B., Avila, N., Chow, C., Novero, L., Wu, H., Ren, P. et al. (2008) Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168: 159–166.

Hadjinicolou, A., Nisar, M., Bhagat, S., Parfrey, H., Chilvers, E. and Ostör, A. (2011) Non-infectious pulmonary complications of newer biological agents for rheumatic diseases – a systematic literature review. Rheumatology 50: 2297–2305.

Hallowell, R. and Horton, M. (2014) Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs 74: 443–450.

Hamblin, M. and Horton, M. (2011) Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Palm Med 2011: 872120.

Herrinton, L., Harrold, L., Liu, L., Raebel, M., Taharka, A., Winthrop, K. et al. (2013) Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 22: 394–402.

Jakubovic, B., Donovan, A., Webster, P. and Shear, N. (2013) Methotrexate-induced pulmonary toxicity. Can Respir J 20: 153–155.

Kawashiri, S., Kawakami, A., Sakamoto, N., Ishimatsu, Y. and Eguchi, K. (2012) A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocolizumab. Rheumatol Int 32: 4023–4026.

Koduri, G., Norton, S., Young, A., Cox, N., Davies, P., Devlin, J. et al. (2010) Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology 49: 1483–1489.

Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T. et al. (2011) Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol 21: 343–351.

Kouba, D., Chung, K., Nishiyaama, T., Vindevoghel, L., Kon, A., Klement, J. et al. (1999) Nuclear factor-κB mediates TNF-α inhibitory effect on α2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J Immunol 162: 4226–4234.

Kremer, J., Alarcon, G., Weinblatt, M., Kaymakcian, M., Macaluso, M., Cannon, G. et al. (1997) Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 40: 1829–1837.
Kuroki, M., Noguchi, Y., Shimono, M., Tomono, K., Tashiro, T., Obata, Y. et al. (2003) Repression of bleomycin-induced pneumopathy by TNF. *J Immunol* 170: 567–574.

Lamblin, C., Bergoin, C., Saelens, T. and Wallaert, B. (2001) Interstitial lung diseases in collagen vascular diseases. *Eur Respir J* 18: S69–S80.

Maradit-Kremers, H., Nicola, P., Crowson, C., Ballman, K. and Gabriel, S. (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 52: 722–732.

Miyazaki, Y., Araki, K., Vesin, C., Garcia, I., Kapanic, Y., Whitsett, J. et al. (1995) Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. *J Clin Invest* 96: 250–259.

Mohr, M. and Jacobi, A. (2011) Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. *Scand J Rheumatol* 40: 400–401.

Mori, S., Koga, Y. and Sugimoto, M. (2012) Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. *Respir Med* 106: 1591–1599.

Nakashita, T., Ando, K., Kaneko, N., Takahashi, K. and Motojima, S. (2014) Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis. *BMJ Open* 4: e005615.

Panopoulos, S. and Sfikakis, P. (2011) Biological treatments and connective tissue disease associated interstitial lung disease. *Curr Opin Pulm Med* 17: 362–367.

Pearce, F., Johnson, S. and Courtney, P. (2012) Interstitial lung disease following certolizumab pegol. *Rheumatology* 51: 578–580.

Perez-Alvarez, R., Perez-de-Lis, M., Diaz-Lagares, C., Pego-Reigosa, J., Retamozo, S., Bove, A. et al. (2011) Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. *Semin Arthritis Rheum* 41: 256–264.

Picchianti Diamanti, M., Germano, V., Bizzì, E., Laganà, B. and Migliore, A. (2011) Interstitial lung disease in rheumatoid arthritis in the era of biologics. *Pulm Med* 2011: 931342.

Raj, R. and Nugent, K. (2013) Leflunomide-induced interstitial lung disease (a systematic review). *Sarcoidosis Vasc Diffuse Lung Dis* 30: 167–176.

Roubille, C. and Harauoui, B. (2014) Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. *Semin Arthritis Rheum* 43: 613–626.

Saravanan, V. and Kelly, C. (2004) Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. *Rheumatology* 43: 143–147.

Saravanan, V. and Kelly, C. (2006) Drug-related pulmonary problems in patients with rheumatoid arthritis. *Rheumatology* 45: 787–789.

Sawada, T., Inokuma, S., Sato, T., Otsuka, T., Saeki, Y., Takeuchi, T. et al. (2009) Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. *Rheumatology* 48: 1069–1072.

Schnabel, A., Richter, C., Bauerfeind, S. and Gross, W. (1997). Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. *Thorax* 52: 377–379.

Schuiller, A., Coudurier, M., Lega, J., Khouatra, C., Cottin, V. and Cordier, J. (2010) Interstitial lung disease and anti-TNF-alpha therapy in rheumatoid arthritis: two different patterns? *Rev Mal Respir* 27: 232–237.

Searles, G. and McKendry, R. (1987) Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. *J Rheumatol* 14: 1164–1171.

Smolen, J., Landewé, R., Breedveld, F., Dougdos, M., Emery, P., Gaujoux-Viala, C. et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis* 69: 964–975.

Soubrier, M., Jeannin, G., Kemeny, J., Tournadre, A., Caillot, N., Caillaud, D. et al. (2008) Organizing pneumonia after rituximab therapy: two cases. *Joint Bone Spine* 75: 362–365.

Sullivan, D., Ferris, M., Nguyen, H., Abboud, E. and Brody, A. (2009) TNF-α induces TGF-β1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. *J Cell Mol Med* 13: 1866–1876.

Takeuchi, T., Tatsuki, Y., Mogami, Y., Ishiguro, N., Tanaka, Y., Yamanaka, H. et al. (2008) Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. *Ann Rheum Dis* 67: 189–194.

Vassallo, R., Matteson, E. and Thomas, C. (2002) Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-α inhibition. *Chest* 122(3): 1093–1096.

Wada, T., Akiyama, Y., Yokota, K., Sato, K., Funakubo, Y. and Mimura, T. (2012) A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of
abatacept. *Nihon Rinsho Meneki Gakkai Kaishi* 35(5): 433–438.

Wagner, S., Mehta, A. and Laber, D. (2007) Rituximab-induced interstitial lung disease. *Am J Hematol* 82(10): 916–919.

Wells, A. and Hirani, N.; On behalf of the British Thoracic Society Interstitial Lung Disease Guideline Group, a subgroup of the British Thoracic Society Standards of Care Committee, in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax* 63(Suppl. V): v1–v58.

Wendling, D., Vidon, C., Godfrin-Valnet, M., Rival, G., Guillot, X. and Prati, C. (2013) Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis. *Joint Bone Spine* 80: 670–671.